Whereas, screening for aPL is mandatory during the investigation of individuals with suspected recent-onset APS or SLE, the clinical value of longitudinal aPL analyses in those patients with an established SLE diagnosis remains uncertain. This evidence concerns the gene FASLG and autoimmune polyendocrinopathy.